ANL
Adlai Nortye Ltd.
Biotechnology · Healthcare · United States
9.55
close · 2026-10-30
value
40
cheaper than peers40
quality
33
stronger fundamentals33
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | -5.5% | 63 |
| price to book | 2.86× | 58 |
| cash flow yield, 1 year ago | -8.5% | 53 |
| earnings yield, latest year | -11.6% | 51 |
| cash flow yield, 3 years ago | -7.2% | 50 |
| cash flow yield, 2 years ago | -9.2% | 49 |
| earnings yield, 3 years ago | -16.7% | 49 |
| earnings yield, 1 year ago | -17.0% | 48 |
| earnings yield, 2 years ago | -79.2% | 21 |
| price to sales | 123.00× | 12 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 178.1% | 83 |
| operating margin | -330.5% | 39 |
| return on equity | -414.0% | 4 |
3 of 4 measures available
Facts
| market cap | $615M |
| free cash flow | -$37.7M |
| employees | 109 |
| first trade | 2023-09-29 |
| next earnings | not reported |
| fundamentals updated | 2026-07-26 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.11 | -1.62 | -7.56 | -1.59 | not reported |
| free cash flow | -$33.6M | -$52.0M | -$56.9M | -$44.5M | not reported |
| net income | -$35.5M | -$51.9M | -$109.2M | -$58.8M | not reported |
| revenue | $5.0M | $0 | $0 | $0 | not reported |
| unusual items | $1,000 | not reported | $62,000 | $1.0M | $72,000 |